Therefore, the addition of MBX-4888A to the standard of care regimen (2HRZE/HR) resulted in quantifiable improvements in achieving durable cure that failed to reach statistical significance within the limitations of this trial design.
← all excerpts
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
1
—
—